Loading...
4D pharma plc
LBPS•NASDAQ
Healthcare
Biotechnology
$1.65
$0.00(0.00%)

Over the last four quarters, 4D pharma plc achieved steady financial progress, growing revenue from $0.00 in Q2 2018 to $52750.00 in Q2 2019. Gross profit stayed firm with margins at 100% in Q2 2019 versus N/A in Q2 2018. Operating income totaled -$7.23M in Q2 2019, maintaining a -13702% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$6.91M. Net income rose to -$6.02M, with EPS at -$0.09. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan